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Brain ageing is associated with cognitive decline and 
neurodegeneration. Normal ageing often leads to levels 
of decline in cognition, with estimates of a fifth of 
people over 71 affected by impairment that is not 
classed as dementia [1]. Loss of mitochondrial 
functionality is implicated as a key factor leading to age 
related decline and the development of many neuro-
degenerative diseases. Increasing our understanding of 
the changes that occur in the normal process of ageing 
is crucial to help distinguish between the biological 
features of disease and that of ageing itself. Delineating 
the expected changes within the lifetime of a mammal 
provides entry points to examine endogenous 
protective and degenerative pathways, these lend 
themselves as biomarkers or can present novel 
treatment targets. 
 
                                                         Research Paper 
Ageing research has focussed on the extension of 
lifespan. The mitochondrial free-radical theory of 
ageing suggests that reactive oxygen species (ROS) 
produced by the mitochondria cause a decline of 
molecular function, resulting in ageing [2]. Critically, 
the balance of beneficial and deleterious effects of 
mitochondrial ROS within a tissue during a lifetime still 
needs to be determined [3]. Recent evidence supporting 
a role for ROS in ageing found that increasing NADPH, 
by upregulation of the enzyme glucose-6-phosphate 
dehydrogenase (G6PD) in mice increased antioxidant 
defences which delayed ageing [4]. Mitochondrial 
dysfunction is a common feature of ageing and 
neurodegeneration and certain mitochondrial proteins 
have been shown to undergo oxidative damage in both 
of these processes [5-7]. However, ROS are unlikely to 
be the only factors contributing to age-related mito-
chondrial dysfunction. An understanding  of  how  mito- 
















role  in  the  conversion  of  carbon  dioxide  and  water  into  bicarbonate  and  protons.  However,  there  is  little
information  about  carbonic  anhydrase  isoforms  during  the  process  of  ageing.  Mitochondrial  dysfunction  is
implicit  in ageing brain and muscle. We have  interrogated  isolated mitochondrial  fractions  from young adult
and middle aged mouse brain and skeletal muscle. We find an increase of tissue specific carbonic anhydrases in
mitochondria from middle‐aged brain and skeletal muscle. Mitochondrial carbonic anhydrase II was measured
in the Purkinje cell degeneration (pcd5J) mouse model.  In pcd5J we find mitochondrial carbonic anhydrase  II  is
also  elevated  in  brain  from  young  adults  undergoing  a  process  of  neurodegeneration.  We  show  C.elegans
exposed  to carbonic anhydrase  II have a dose  related shorter  lifespan suggesting  that high CAII  levels are  in
themselves life limiting. We show for the first time that the mitochondrial content of brain and skeletal tissue
are  exposed  to  significantly  higher  levels  of  active  carbonic  anhydrases  as  early  as  in middle‐age.  Carbonic
anhydrases associated with mitochondria could be targeted to specifically modulate age related  impairments
and disease.  
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chondrial composition changes with age can shed light 
on the mechanisms affecting these organelles 
throughout the lifetime of mammals. A complication, 
when looking at diseases of ageing, is the inability to 
separate the effect of normal ageing from disease-
related changes in the mitochondrion, for example in 
Parkinson’s Ddisease where mitochondrial changes are 
clearly important, yet not always specifically 
distinguishable from the effects of ageing [5, 8].  
 
Proteomics targeted specifically at the mitochondrial 
fraction of the cell is a powerful approach to identify the 
expected age-related changes in tissues. A few studies 
have been reported where mitochondrial proteins have 
been examined in normal brain tissue [9, 10]. Existing 
studies of skeletal muscle senescence suggest that 
mitochondrial enzymes are largely increased in 
abundance, though how this information fits with 
decreased complex I activity in ageing mitochondria has 
not yet been determined [11].  
 
Our study stems from an interest in mitochondrial 
proteins within tissues with a high capacity for 
oxidative phosphorylation.  Both the brain and skeletal 
muscle undergo a degree of decline in advanced age. 
We profiled proteins of mitochondrial fractions isolated 
from young (~8weeks) and old (78 weeks) mouse brain 
and skeletal muscle. It is pertinent to point out that our 
samples were deliberately chosen to reflect youth versus 
middle-age, rather than true old-age (old mouse would 
be >104 weeks) [12]. Our intention was to maximise the 
possibility of identifying early changes that may be 
occurring prior to detectable functional losses rather 
than the ‘gravestones’ heralding end stage dysfunction. 
While it is illuminating to interrogate the proteome of a 
particular biological entity, neither of these are closed 
systems. Our study highlights the importance of making 
assessments across these groupings. We show that the 
pharmaceutical target carbonic anhydrase II is increased 
with age in mitochondria. To investigate the potential 
importance of changing levels of these proteins we 
looked to see whether carbonic anhydrases are also 
changed in a similar manner in the Purkinje Cell 
Degeneration (pcd5J) mouse model of neuro-
degeneration. The pcd5J mouse is an excellent model to 
study the effect of a pure mitochondrial neuro-
degenerative phenotype that occurs early in life [13-15, 
7].  We compared our findings in the neuronal and non-
neuronal tissues with what we found in pcd5J to 
understand whether the levels of carbonic anhydrase 
found are likely to be a protective or dysfunctional 
alteration. We now are able to provide the molecular 
context of normal mitochondrial ageing which needs to 
be fully considered as carbonic anhydrase inhibitor 
therapy becomes more widely applied in diseases 
affecting our ageing populations. 
RESULTS AND DISCUSSION 
 
The mitochondrial proteome is different in young 
and old murine skeletal muscle tissue 
 
Six proteins were selected to have changed when 
comparing the young (4-11 week) and old (78 week) 
skeletal muscle mitochondrial proteomic profiles 
(Figure 1A).  Carbonic anhydrase III (discussed later), 
calsequestrin and Voltage Dependent Anion Channel 
1(VDAC1) increase with age in the old skeletal muscle 
mitochondria (p<0.05). Calsequestrin increases with a 
greater than two-fold change between the young and 
older mitochondria. It has recently been shown that loss 
of calsequestrin leads to mitochondrial dysfunction and 
oxidative stress in skeletal muscle [16]. It could be 
interpreted therefore that an upregulation of calse-
questrin in this case is a protective response rather than 
being reflective of muscle decline; a study in 
postmenopausal women also identifies a (smaller fold) 
increase in total skeletal muscle calsequestrin [17]. 
Overexpression of calsequestrin in cardiomyocytes 
suggests that endoplasmic reticulum calcium stores may 
be enhanced perinuclearly to provide an independent 
compensatory effect in the case of misregulated calcium 
homeostasis. Mitochondria also accumulate peri-
nuclearly and are regulators of calcium signalling 
providing more evidence that the upregulation in 
calsquestrin that we observe is protective in ageing 
skeletal muscle [18]. In skeletal muscle mitochondria 
we can confirm definite changes in haemoglobin 
subunit alpha, ATP synthase and VDAC1. These 
mitochondrial proteins have previously been shown to 
be differentially regulated in ageing and our data 
confirm that these are likely important regulators of 
ageing in skeletal muscle mitochondria [5, 19, 20]. 
 
The mitochondrial proteome is also distinctly 
different between young and old murine brain tissue 
 
In brain mitochondrial fractions our top list defines 
pyruvate dehydrogenase E1, alpha enolase and NADH 
flavoprotein 2 as changed between the young (4-11 
weeks) and old (78 weeks) brain mitochondrial proteome 
(Figure 1B). Pyruvate dehydrogenase is known to decline 
through the brain with age and enolase has recently found 
to be decreased on the CD4(+) T cell surface in a small 
study of older males [21]. However, this is the first time 
these have been shown to be changed in association with 
ageing of the mitochondrial organelle. NADH dehydro-
genase flavoprotein 2 (NDUFV2) a complex 1 protein is 
confirmed to be increased in the old mitochondria 
(p<0.005), agreeing with the perceived increase in 
complex 1 enzymes reported in senescent muscle [11] 
(Figure 1D). Mutations and variation in NDUFV2 are 
associated with disorders of the brain and ageing [22-25]. 
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Our finding could suggest that the variations and 






















































most detrimental when upregulated, perhaps for 











































































Carbonic anhydrase II and III are significantly 
increased in mitochondria isolated from older mice 
 
Interestingly we show that two isoforms of carbonic 
anhydrase (CAII and CAIII) increase in both 78 week 
old brain mitochondria and 78 week old skeletal muscle 
mitochondria, respectively. Carbonic anhydrases are 
zinc metalloenzymes that catalyse the reversible 
hydration of carbon dioxide to bicarbonate. Carbonic 
anhydrase II binds to Na+/H+ exchanger altering pH 
[26]. Carbonic anhydrases also catalyse the reversible 
hydration of CO2, HCO3- and H+ [27]. Therefore, the 
role of carbonic anhydrases in maintaining the pH 
environment of the cell and specifically the 
mitochondrion is important to delineate. 
 
CAIII is the muscle-specific isoenzyme [28] whilst 
CAII is located in the cytosol and widely expressed in 
most tissues [29]. In our study carbonic anhydrase III is 
significantly increased in old skeletal muscle 
mitochondria compared with young muscle 
mitochondria p<0.005 (t-test) (Figure 1C).  We also see 
that CAII is significantly increased in mitochondria 
isolated from old brain tissue p<0.05 (t-Test) (Figure 
1E). Calculated probability scores suggest that CAII and 
CAIII are not predicted to cleave into mitochondrial 
targeted forms. It is possible that these proteins 
associate very tightly with the mitochondrion without 
necessarily entering the organellar space [30, 31]. 
Carbonic anhydrase III is not essential for survival in 
mouse and has been known for some time to increase in 
muscle with ageing and contraction [28, 32, 35]. A role 
in mitochondrial function has not yet been postulated 
for it, though we clearly observe a significant increase 
in the quantity of this protein in aged-muscle 
mitochondrial fractions.  
 
CAII, belongs to the group of these isoenzymes that are 
pharmacologically targeted by inhibitors (such as 

















glaucoma, cancer osteoporosis, epilepsy, neuro-
psychiatric disorders and acute mountain sickness [36-
39]. Methazolamide also a carbonic anhydrase inhibitor, 
has also been shown recently to prevent amyloid-beta 
induced mitochondrial dysfunction and is neuroprotective 
in mouse models of Alzheimer’s disease [40].   
 
The esterase activity of carbonic anhydrase II is 
increased in the mitochondrial fraction of brain 
tissue from older animals 
 
We tested whether an upregulation of CAII protein 
corresponded with an increase in enzymatic activity.  We 
measured the esterase activity of carbonic anhydrase II 
by monitoring the hydrolysis of 4-nitrophenyl acetate to 
form 4-nitrophenol. Mitochondria from aged brain tissue 
exhibited a higher rate of change in absorbance in 
comparison to mitochondria from young brain tissue 
throughout the 5-minute assay (Figure 2A). The rate of 
change at 1, 2 and 4 minutes were significantly higher in 
mitochondria from the old brain tissue (t-test) p<0.05. 
Our data show that the expression of CAII increases with 
ageing and this can be measured by the activity of CAII 
which is greater per mitochondrial unit in old versus 
young brain mitochondrial fractions.  
 
Carbonic anhydrase II protein levels in retina 
mitochondria significantly increase in aged animals 
 
Advanced age leads to an increased risk of developing 
neurodegenerative diseases. Glaucoma is a neuro-
degenerative disease that has been associated with 
oxidative stress and age related mitochondrial dys-
function [41, 42]. We investigated the protein levels of 
CAII in retina mitochondria from aged mice (78 
weeks). We observe a large increase in CAII in the 
retina mitochondria from aged mice in comparison to 
young mice (4-11 weeks), p<0.05 (Figure 2B). Our data 
indicate that CAII protein levels also increase in the 
retina with age.  
probability was calculated (Mitoprot) and is shown along with predicted cleavage sites and sequence. (B) Identification of proteins that
change with age in the skeletal muscle mitochondrial proteome. Four protein spots were selected after (SameSpots) analysis comparing
murine  brain mitochondria  aged  4‐11 weeks  (young)  (n=3)  and  78 weeks  (old)  (n=3). Representative  protein  spot  images,  statistical
analyses  (one‐way ANOVA)  and  identities of  the proteins  (MASCOT)  are  shown. Mitochondrial  localisation probability was  calculated
(Mitoprot) and  is  shown along with predicted  cleavage  sites and  sequence.  (C) Carbonic anhydrase  III protein  levels  increase  in aged
skeletal muscle mitochondria. Carbonic anhydrase III, normalised to GAPDH, is significantly increased in 78 week old (n=4) skeletal muscle
mitochondria  compared with  4‐11 week  old  (n=4)  skeletal muscle mitochondria,  p=0.0105.  (D) NADH  dehydrogenase  flavoprotein  2
protein  levels  increase  in  aged  brain mitochondria.    NADH  dehydrogenase  flavoprotein  2,  normalised  to  beta‐actin,  is  significantly




























Carbonic anhydrase II protein levels significantly 
increase in brain mitochondria from the 
neurodegenerative mouse model pcd5J 
 
The Purkinje Cell Degeneration mouse, pcd, is an 
autosomal recessive mutant and a model of neuro-
degeneration. The pcd5J mouse model has a mutation in 
the Nna1 gene that encodes a protein that is localised in 
the mitochondrion. Initially the pcd5J mice are born with 
normal development of Purkinje cells but after 15 days 














































over a 99% loss of Purkinje cells by around 3 weeks of 
age [13].  We used the pcd5J mouse model to investigate 
whether the changes in CAII levels are specific to the 
ageing process or are also a sign of neurodegeneration. 
Mitochondria were isolated from the cerebellum of pcd5J 
and aged matched wild type animals (10-13 weeks). CAII 
protein levels are significantly elevated in the pcd5J 
cerebellum mitochondria compared to wild type 
mitochondria, p<0.05 (Figure 3A). We propose that the 
increase in CAII in the brain with ageing is an early 





























Figure  3.  (A)  Carbonic  anhydrase  II  protein  levels  increase  in  the  neurodegenerative mouse model,  pcd5J  cerebellum




mice aged 10‐13 weeks. Replicates were obtained  from  individual animals.  (C) Carbonic anhydrase  II accumulates  in  the
pcd5J retina mitochondria. Carbonic anhydrase II levels are significantly higher in pcd5J mice compared to wild type animals,
p=0.0019. Replicates were  obtained  from  individual  animals  (wild  type  n=6,  pcd5J  n=6),  all  animals were  between  9‐17
weeks old. Columns display mean activity ± SEM. * = p<0.05, **= p<0.03 two‐tailed unpaired t‐test with Welch’s correction.
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Carbonic anhydrase III protein levels are not 
significantly different between pcd5J and wild type 
skeletal muscle mitochondria 
 
Skeletal muscle is unaffected by the loss of Nna1 
function in pcd5J animals. The muscle specific isoform 
of carbonic anhydrase CAIII was found to be altered in 
the ageing skeletal muscle mitochondria. We wanted to 
test whether CAIII protein levels changed in the pcd5J 
mouse muscle to see whether the changes in CAII in 
neural tissues were indeed specific for ageing and 
neurodegeneration or whether the pcd5J mutant has a 
systemic alteration in carbonic anhydrases, even in 
unaffected tissues. We compared pcd5J skeletal muscle 
from the young mice that already showed signs of 
neurodegeneration in retina and cerebellum with age-
matched wild type animals (10-13 weeks). We found 
that the quantity of CAIII is not significantly different 
in the pcd5J and wild type animals (Figure 3B). Since 
the pcd5J animals have functionally healthy skeletal 
muscle it is unsurprising that there is no significant 
difference between the quantity of CAIII in the wild 
type and mutant animals. However, this suggests very 
strongly that the alterations in carbonic anhydrases 
found in ageing and neurodegeneration are a harbinger 
of the dysfunction which ensues. 
 
The neurodegenerative mouse model, pcd5J, also 
shows significantly increased carbonic anhydrase II 
protein levels in retinal mitochondria 
 
Retinal degeneration is a feature of the pcd5J animals 
and so we used this mouse model to investigate whether 
CAII increases in mitochondria in a disease state. We 
show CAII protein levels significantly increase in retina 




















mice (2-4 weeks old), p<0.05 (Figure 3C). Our data 
suggest that the accumulation of CAII in retina 
mitochondria occurs during the normal ageing process 
and that increasing levels of CAII is also a feature of 
retinal degeneration. The CAII inhibitor dorzolamide 
hydrochloride is commonly used in the treatment of 
glaucoma to improve ocular perfusion. Dorzolamide 
hydrochloride has also been suggested to act as 
antioxidant, exerting its effect through intact 
mitochondria [43]. We now suggest that the action of 
dorzolamide hydrochloride in glaucoma should be 
analysed for its likely effect on the raised CAII levels 
we find in ageing retinal mitochondria. 
 
Increased carbonic anhydrase II reduces lifespan 
 
The six alpha-carbonic anhydrase isoforms 1 to 6 are 
encoded for in the Caenorhabditis elegans genome 
(cah-1, cah-2, cah-3, cah-4, cah-5 and cah-6) [44]. 
Wormbase searches revealed that the murine (Mus 
musculus) CAII gene has similar homology to the 
C.elegans gene cah-3. Both cah-3 and cah-4 in 
C.elegans are orthologs of the murine carbonic 
anhydrase II gene [45]. Ensembl searches showed that 
the amino acid sequence for the murine carbonic 
anhydrase II protein has sequence homology with four 
carbonic anhydrase proteins in C.elegans, cah-3, cah-5, 
cah-1 and cah-2. We tested whether the increase in 
CAII is a protective mechanism or a sign of dysfunction 
by exploring the effect of CAII on C.elegans. C. 
elegans (strain CB5600) were treated with three 
different concentrations of CAII (1500 units, 150 units 
and 15 units). Animals treated with CAII have a 
significant reduction in lifespan p=0.0006 (Log-rank 
test). The animals show a dose dependant response to 






















Figure 4. Exposure  to carbonic anhydrase  II  treatment significantly shortens  lifespan of
C.elegans.  C. elegans (strain CB5600) exposed to carbonic anhydrase II were recorded by
Kaplan Meier  survival  plot  (Log‐rank  test,  p=0.0006).  Three  concentrations  of  carbonic
anhydrase II 1500 units, 150 units and 15 units were used (10 animals in each condition).  
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spans were 6, 8 and 12 days for animals treated with 
1500 units, 150 units, 15 units respectively. In the same 
experiments control animals had a median lifespan of 
19 days. The absolute maximum lifespans were 13, 14 
and 18 days for animals treated with 1500 units, 150 
units and 15 units respectively and the control animals 
had an absolute maximum lifespan of 31 days.  Animals 
treated with the highest concentration of CAII (1500 
units) had a 58% reduction in lifespan compared to the 
control animals, whilst animals treated with 150 and 15 
units showed a reduction in lifespan by 55% and 42% 
respectively compared to the controls. Based on these 
findings we suggest that carbonic anhydrase inhibitors 
could be targeting the effects of mitochondrial ageing in 
neurons by reducing carbonic anhydrase levels to 
physiologically more youthful levels. CAII is likely to 




We present a picture of complex proteomic profile 
changes in mitochondrial fractions with ageing. In 
particular, we observe accumulations of carbonic 
anhydrase isoenzymes with increased age. CAII protein 
levels were also found to increase in the cerebellum and 
retina mitochondria of the neurodegenerative disease 
mouse model, pcd5J. We propose that increased 
quantities of CAII play a detrimental role in the ageing 
process. Therapeutic use of carbonic anhydrase 
inhibitors are likely to be exerting an effect on 
mitochondrial populations and may be offering 
protection through maintenance or stabilisation of 
carbonic anhydrase to physiologically young levels.  
 




Brain, skeletal muscle and retinal tissue were dissected 
from young (4-11 week old) and old (78 weeks) 
C57BL/6J mice (Charles River). The Purkinje cell 
degeneration mice (pcd5J) and wild type animals (9-17 
weeks old) were sourced from the University of 
Nottingham.  
 
2D gel analysis 
 
Mitochondrial samples, 4-11 weeks brain (n=5), 78 
weeks brain (n=5), 4-11 weeks skeletal muscle (n=3) 
and 78 weeks skeletal muscle (n=3), were subject to iso-
electric focussing using ZOOM IPG (Life 
Technologies) system and pH 3-10 (non-linear) ZOOM 
IPG strips following the manufacturers protocol. Gels 
were stained (SimplyBlue™ SafeStain, Life 
Technologies) and imaged (ImageQuant 300, GE 
Healthcare Life Sciences). Analysis was performed 
using SameSpots software (Totallab). Protein spots with 
a p value of less than 0.15 and a fold change greater 
than 1.2 were further analysed (one-way ANOVA). 





Western blotting was carried out as described 
previously [5].  
 
Antibody dilutions: Carbonic anhydrase II ab6621 
(Abcam) 1:7000 dilution in 3% (w/v) BSA in TBS-T; 
NADH dehydrogenase flavoprotein 2 ARP57510-PO50 
(Cambridge Bioscience) 1:5000 dilution in 3% (w/v) 
BSA in TBS-T; Beta-actin ab8227 (Abcam) 1:5000 
dilution in 3% (w/v) BSA in TBS-T; Carbonic 
anhydrase III AP7633a (ABGENT) 1:2500 dilution in 
3% (w/v) BSA in TBS-T, GAPDH G9545 (SIGMA) 
1:5000 dilution in 3% (w/v) BSA in TBS-T and COXIV 
(ab16056) 1:5000 dilution in 3% (w/v) BSA in TBS-T. 
Brain mitochondrial samples were normalised to beta-
actin level. The average of four samples for each 
condition (old and young) were plotted showing the 
mean +/- SEM. The muscle mitochondrial samples were 
normalised to GAPDH level. The average of the four 
samples for each condition (old and young) were plotted 
showing the mean +/- SEM. The retina mitochondrial 
samples were normalised to COXIV level. The average 
of the six samples for each condition (young and old) 
were plotted showing the mean +/- SEM. Statistical 
analyses (unpaired t-tests with Welch’s correction) were 
carried out in GraphPad Prism.  
 
Carbonic anhydrase II enzyme assay 
 
Esterase activity of carbonic anhydrase II was measured 
by monitoring the release of 4-nitrophenol at A348 nm 
in a Thermo Scentific Helios Epsilon spectrophotometer 
using standard methods [46]. Cuvettes contained 900 μl 
of 15 mM Tris Sulphate Buffer, pH 7.6 at 0°C (Sigma), 
500 μl of 3 mM 4-nitrophenyl-acetate (Sigma) and 30 
μg/μl of mitochondrial sample (3 mitochondrial 
preparations and 3 replicates for each condition, 4-11 
weeks and 78 weeks). The rate of change in absorbance 
of the assay was plotted.  Unpaired t-tests (GraphPad 
Prism) were carried out at each time point.   
 
Carbonic anhydrase II lifespan study 
 
CB5600 C. elegans strain is superficially wild type and 
expresses GFP in nuclei and mitochondria of body-wall 
muscles. Animals were maintained on solid NGM agar 
plates seeded with the Escherichia coli strain OP50 
using standard methods and aged-synchronized [47, 48].   
Animals were exposed to three concentrations of 
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synthetic carbonic anhydrase II (C2522 SIGMA) 1500 
units, 150 units and 15 units. Control plates had 20 μl of 
dH20 spotted on to the surface whilst treated plates had 
20 μl of carbonic anhydrase II spotted on. Each plate 
contained 10 L1 larvae (n=40). Animals were scored 
every day and those not moving that did not respond to 
stimulation with a needle were recorded as dead. The 
experiment was maintained at 20°C.  Kaplan-Meier 
survival curve and statistical analysis (log-rank, Mantel-




Animals were bred and housed in accordance with strict 
Home Office stipulated conditions. The overall 
programme of work (in respect to the original UK 
Home Office Project Licence application) is reviewed 
by the Animal Welfare and Ethical Review Body at the 
University of Nottingham and then scrutinised by the 
UK Home Office Inspectorate before approval by the 
Secretary of State. Individual study protocols link to the 
overarching Home Office Project Licence and are made 
available to the Named Animal Care and Welfare 
Officer, the Named Veterinary Surgeon (both are 
members of the AWERB), the animal care staff and the 
research group. The Project Licence Number for the 
breeding and maintenance of this genetically altered 
line of mice is PPL 40/3576. The mice are typically 
group housed and maintained within solid floor cages 
containing bedding and nesting material with additional 
environmental enrichment including chew blocks and 
hiding tubes. Cages are Individually Ventilated Cage 
Units within a barrier SPF unit to maintain bio-security. 
Animals are checked daily by a competent and trained 
animal technician. Any animal giving cause for 
concern such as subdued behaviour, staring coat, loss 
of weight or loss of condition will be humanely killed 





This work on the biology of the mitochondrion is 
dedicated to Gottfried Schatz. 
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Supplementary Figure 1.  (A) The peptides  identified  from spot 6 matched  the peptide sequence of  the protein calsequestrin.
The peptides found in spot 6 are highlighted in red and cover 9.5% of the peptide sequence for calsequestrin. (B) The peptides in
spot 26 matched  the peptide sequence of voltage‐dependent anion‐selective channel protein 1  (VDAC 1). The peptides  found  in




of  protein  carbonic  anhydrase  III.  The  peptides  found  in  spot  47  are  highlighted  in  red  and  covers  19%  of  protein  carbonic
anhydrase III peptide sequence. F) The peptides in spot 60 matched the peptide sequence of protein haemoglobin subunit alpha.
The peptides found in spot 60 are highlighted in red and covers 21% of protein haemoglobin subunit alpha peptide sequence. 





















The peptides  found  in spot 133 are highlighted  in  red and covers 7% of carbonic anhydrase  II peptide sequence.
Carbonic anhydrase II was found to increase in abundance in the aged brain mitochondrial proteome. (B) In addition
to  using  the MASCOT  database  peptide  de  novo  sequencing was  also  used  to  identify  protein  spot  108.    The
peptides  identified  in protein spot 108 matched 14% of the sequence for the protein pyruvate dehydrogenase E1
subunit β (matching peptides are highlighted  in blue, purple and green). (C) The peptides  in spot 75 matched the
peptide sequence of alpha enolase. The peptides found  in spot 75 are highlighted  in red and covers 13% of alpha
enolase peptide sequence. Alpha enolase was found to increase in abundance in the aged mitochondrial proteome.
(D) The peptides in spot 153 matched the peptide sequence of NADH dehydrogenase flavoprotein 2. The peptides
found in spot 153 are highlighted in red and covers 12% of alpha enolase peptide sequence. NADH dehydrogenase
flavoprotein 2 was found to increase in abundance in the aged mitochondrial proteome. 
